344 related articles for article (PubMed ID: 27730820)
1. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
[TBL] [Abstract][Full Text] [Related]
2. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
3. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
Eifler AC; Thaxton CS
Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
[TBL] [Abstract][Full Text] [Related]
5. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
Taha MS; Padmakumar S; Singh A; Amiji MM
Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
[TBL] [Abstract][Full Text] [Related]
6. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
7. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.
Nayak R; Meerovich I; Dash AK
AAPS PharmSciTech; 2019 Apr; 20(4):160. PubMed ID: 30968269
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
9. Mathematical and computational modeling of nano-engineered drug delivery systems.
Shamsi M; Mohammadi A; Manshadi MKD; Sanati-Nezhad A
J Control Release; 2019 Aug; 307():150-165. PubMed ID: 31229474
[TBL] [Abstract][Full Text] [Related]
10. Blood-Vessel-on-a-Chip Platforms for Evaluating Nanoparticle Drug Delivery Systems.
Li Y; Zhu K; Liu X; Zhang YS
Curr Drug Metab; 2018; 19(2):100-109. PubMed ID: 28952434
[TBL] [Abstract][Full Text] [Related]
11. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
Overchuk M; Zheng G
Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
[TBL] [Abstract][Full Text] [Related]
12. Nanotherapeutics in the EU: an overview on current state and future directions.
Hafner A; Lovrić J; Lakoš GP; Pepić I
Int J Nanomedicine; 2014; 9():1005-23. PubMed ID: 24600222
[TBL] [Abstract][Full Text] [Related]
13. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
[TBL] [Abstract][Full Text] [Related]
14. Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics.
Gindy ME; Leone AM; Cunningham JJ
Expert Opin Drug Deliv; 2012 Feb; 9(2):171-82. PubMed ID: 22251440
[TBL] [Abstract][Full Text] [Related]
15. Challenges in development of nanoparticle-based therapeutics.
Desai N
AAPS J; 2012 Jun; 14(2):282-95. PubMed ID: 22407288
[TBL] [Abstract][Full Text] [Related]
16. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
Agarwal V; Bajpai M; Sharma A
Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
[TBL] [Abstract][Full Text] [Related]
17. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
[TBL] [Abstract][Full Text] [Related]
19. Grand challenges in nanomedicine.
Wu LP; Wang D; Li Z
Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110302. PubMed ID: 31753337
[TBL] [Abstract][Full Text] [Related]
20. Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges.
Bose RJC; Ravikumar R; Karuppagounder V; Bennet D; Rangasamy S; Thandavarayan RA
Drug Discov Today; 2017 Aug; 22(8):1258-1265. PubMed ID: 28600191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
